Department of Microbiology and Center of Infectious Disease, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China.
Department of Liver Disease, Third People's Hospital of Shenzhen, Shenzhen, China.
Gastroenterology. 2019 Jun;156(8):2230-2241.e11. doi: 10.1053/j.gastro.2019.02.002. Epub 2019 Feb 8.
BACKGROUND & AIMS: We performed a nationwide, retrospective study to determine the incidence and causes of drug-induced liver injury (DILI) in mainland China.
We collected data on a total of 25,927 confirmed DILI cases, hospitalized from 2012 through 2014 at 308 medical centers in mainland China. We collected demographic, medical history, treatment, laboratory, disease severity, and mortality data from all patients. Investigators at each site were asked to complete causality assessments for each case whose diagnosis at discharge was DILI (n = 29,478) according to the Roussel Uclaf Causality Assessment Method.
Most cases of DILI presented with hepatocellular injury (51.39%; 95% confidence interval [CI] 50.76-52.03), followed by mixed injury (28.30%; 95% CI 27.73-28.87) and cholestatic injury (20.31%; 95% CI 19.80-20.82). The leading single classes of implicated drugs were traditional Chinese medicines or herbal and dietary supplements (26.81%) and antituberculosis medications (21.99%). Chronic DILI occurred in 13.00% of the cases and, although 44.40% of the hepatocellular DILI cases fulfilled Hy's Law criteria, only 280 cases (1.08%) progressed to hepatic failure, 2 cases underwent liver transplantation (0.01%), and 102 patients died (0.39%). Among deaths, DILI was judged to have a primary role in 72 (70.59%), a contributory role in 21 (20.59%), and no role in 9 (8.82%). Assuming the proportion of DILI in the entire hospitalized population of China was represented by that observed in the 66 centers where DILI capture was complete, we estimated the annual incidence in the general population to be 23.80 per 100,000 persons (95% CI 20.86-26.74). Only hospitalized patients were included in this analysis, so the true incidence is likely to be higher.
In a retrospective study to determine the incidence and causes of DILI in mainland China, the annual incidence in the general population was estimated to be 23.80 per 100,000 persons; higher than that reported from Western countries. Traditional Chinese medicines, herbal and dietary supplements, and antituberculosis drugs were the leading causes of DILI in mainland China.
我们进行了一项全国性的回顾性研究,以确定中国大陆药物性肝损伤(DILI)的发病率和病因。
我们收集了 2012 年至 2014 年期间,中国大陆 308 家医疗中心共 25927 例确诊的 DILI 住院患者的数据。我们收集了所有患者的人口统计学、病史、治疗、实验室、疾病严重程度和死亡率数据。每个研究中心的研究人员均被要求根据 Roussel Uclaf 因果关系评估方法,对出院诊断为 DILI(n=29478)的每个病例进行因果关系评估。
大多数 DILI 表现为肝细胞损伤(51.39%;95%置信区间[CI] 50.76-52.03),其次是混合损伤(28.30%;95%CI 27.73-28.87)和胆汁淤积性损伤(20.31%;95%CI 19.80-20.82)。主要的单一药物类别是中药或草药和膳食补充剂(26.81%)和抗结核药物(21.99%)。慢性 DILI 占 13.00%,虽然 44.40%的肝细胞性 DILI 病例符合 Hy's 法则标准,但仅有 280 例(1.08%)进展为肝衰竭,2 例接受了肝移植(0.01%),102 例患者死亡(0.39%)。在死亡病例中,DILI 被判断为主要作用 72 例(70.59%),辅助作用 21 例(20.59%),无作用 9 例(8.82%)。假设 DILI 在全国住院患者人群中的比例与在 66 家完成 DILI 捕获的中心观察到的比例相同,我们估计一般人群的年发病率为 23.80/10 万人(95%CI 20.86-26.74)。本分析仅纳入住院患者,因此实际发病率可能更高。
在一项旨在确定中国大陆 DILI 发病率和病因的回顾性研究中,估计一般人群的年发病率为 23.80/10 万人;高于西方国家报告的发病率。中药、草药和膳食补充剂以及抗结核药物是中国大陆 DILI 的主要原因。